Germany: Novo Nordisk strengthens pipeline in cardiovascular disease with acquisition of Cardior Pharmaceuticals

Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025bn (US$1.11bn), including an upfront payment and additional payments subject to certain development and commercial milestones being achieved. The acquisition […]